JP Morgan Chase
CDAK

JP Morgan Chase’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

JP Morgan Chase’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-79
Closed – – 7561
2023
Q1 		$0 Hold
79
– – ﹤0.01% 7448
2022
Q4 		$0 Sell
79
-1,299
-94% -$855 ﹤0.01% 7234
2022
Q3 		$1K Buy
1,378
+509
+59% +$1.07K ﹤0.01% 6407
2022
Q2 		$3K Sell
869
-9,207
-91% -$32.3K ﹤0.01% 6261
2022
Q1 		$63K Buy
10,076
+2,254
+29% +$14.1K ﹤0.01% 5708
2021
Q4 		$87K Sell
7,822
-2,476
-24% -$34.3K ﹤0.01% 5744
2021
Q3 		$168K Buy
10,298
+4,270
+71% +$76.4K ﹤0.01% 5327
2021
Q2 		$112K Sell
6,028
-22,513
-79% -$432K ﹤0.01% 5504
2021
Q1 		$430K Buy
28,541
+13,383
+88% +$291K ﹤0.01% 4771
2020
Q4 		$489K Buy
+15,158
New +$201K ﹤0.01% 4381

JP Morgan Chase's CDAK Position: Q2 2023 in Review

JP Morgan Chase sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 79 shares.

JP Morgan Chase first reported a position in CDAK in Q4 2020 and held it in 10 quarters. The position peaked at $489K in Q4 2020. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

  • JP Morgan Chase reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Chase sold 79 Codiak BioSciences, Inc. Common Stock shares in Q2 2023.
  • JP Morgan Chase first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • JP Morgan Chase's Codiak BioSciences, Inc. Common Stock position peaked at $489K in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.